ASX ANNOUNCEMENT

16 June 2025

HERAMED PARTNERS WITH RMIT AND DIGITAL HEALTH CRC TO ADVANCE AI-DRIVEN MATERNITY CARE

- HeraMED joins forces with RMIT University (RMIT) and the Digital Health Cooperative Research Centre (DHCRC) in a research partnership to transform maternity care for culturally and linguistically diverse (CALD) women
- The project, titled "New AI Models to Assess Risk of Pre-Term Delivery Linked to Socio-Economic Factors", is grant funded research with an overall project value of $1,245,300
- Data integration into HeraCARE will be undertaken to refine predictive health models and develop new AI-driven tools
- New AI models will be deployed to support real-time clinical decision making and personalised maternity care, increasing access of tailored care to CALD women
- Project will include up to 200 women over 18 months
- An expected outcome is a trained AI predictive model, to be commercialised under Licenced IP between HeraMED and RMIT/DHCRC
- The collaboration will advance HeraMED's 'data-as-an-asset' and commercialisation strategy

HeraMED Limited (ASX: HMD), a leading women's health technology & medical data company, is pleased to announce it has entered into a research and development partnership with RMIT University and the Digital Health Cooperative Research Centre (DHCRC). The initiative will focus on improving maternal health outcomes through the collection and use of data sets including culturally and linguistically diverse (CALD) women through AI-enabled predictive care.

Under the project, titled "AI models to assess risk of pre-term delivery linked to socio-economic factors," HeraMED's proprietary HeraCARE platform will work with a number of health systems to onboard 200 pregnant women using HeraCARE licences to monitor and collect data through personalised care plans. The initiative will use a combination of clinical, biometric, lifestyle and genetic data, with a focus on diversity, inclusion, and clinical applicability.

The project is co-funded by the DHCRC, RMIT and HeraMED, both in-kind and with cash, with an overall project value of $1,245,300.

The project will primarily fund a post-doctoral researcher, HeraCARE licences, HeraBEAT and regulatory compliance. HeraMED's cash contribution to the project will be approximately $250,000 over the 18 month timeframe of the project, while it will also receive fees relating to HeraCARE licences and HeraBEAT devices. HeraMED's in-kind contribution is part of its allocated budget for product R&D and evidence-based research to develop innovative models of care.

This partnership complements HeraMED's strategy of a customer-first focus, as well as its focus on non-dilutive funding to advance the capabilities of HeraCARE. The Company expects the HeraCARE platform to be enhanced with the integration of advanced AI models, which can be monetised via subscription-based models, licensing, and integration with third-party health systems. The CALD dataset will be a unique resource to inform clinical decision making and generate insights relevant to both healthcare providers and the broader health system.

A focus of the project is developing AI-driven tools to predict adverse pregnancy outcomes through integrating culturally diverse datasets with the key output being a trained AI model.

DHCRC CEO Annette Schmiede said, "The project showcases the value of digital innovation and better access to data to deliver more equitable access to care. Women from diverse backgrounds often encounter significant challenges when navigating the healthcare system," Ms Schmiede said. She continued, "Language barriers, lower health literacy, and insufficient data can expose them to a higher risk of receiving lower-quality healthcare, inadequate service delivery, and poorer health outcomes compared to other Australians.

This project will look to address this challenge in maternity care by developing proprietary AI models to create a person-centred care model that will improve patient outcomes, save resources and reduce costs for care providers."

In addition, the project aligns closely with RMIT's research expertise and ongoing initiatives led by Associate Professor Sonika Tyagi. Professor Tyagi is a recognised leader in digital health and bioinformatics, specialising in artificial intelligence (AI) applications for biological and clinical research, particularly genomics and maternal health.

HeraMED Managing Director and CEO, Anoushka Gungadin, said, "With 51% of Australians having at least one parent born overseas, the need for culturally informed healthcare is critical and relevant. Current maternal-fetal datasets lack representation from CALD women, leading to biases in diagnostics and care. This challenge is mirrored in genomic research, where underrepresentation on minority groups skews risk assessments and treatment efficacy. This partnership underscores HeraMED's commitment to leveraging cutting-edge technology to address critical healthcare challenges. Through this partnership, we're enabling HeraCARE to generate more inclusive, AI-driven insights, that clinicians can use to improve outcomes, reduce system costs, and deliver value-based care. Having the expertise and passion of the teams at RMIT & DHCRC, this partnership isn't just about innovation, it's about redefining equity, access and fit-for-purpose solutions in healthcare. Investing in women's health is investing in the health of generations to come."

The collaboration will involve:

- Diverse Data Integration: CALD-specific data collection via 200 pregnant mothers onboarded to HeraCARE will address historical underrepresentation, enhancing AI generalisability and reducing biases
- Enhancing the RMIT-based Pregnancy Knowledge Base (PKB) as a central data and analytics resource to be used for research purposes
- Supporting real-time remote monitoring through HeraCARE, connected to all required smart devices used in this research project
- AI-Driven Solutions: New Advanced AI model will provide real-time risk insights and adaptive treatment pathways, integrated seamlessly into clinical workflows via HeraCARE's capabilities

- Genomic Relevance: Aligning with global efforts to improve genomic inclusivity, the project will identify population-specific biomarkers
- Developing digital tools and decision-support systems for scalable commercial use across hospitals, clinics, and public health systems.
- 18 month project timeline
- Agreed licencing terms between HeraMED and RMIT/DHCRC for new IP

The collaboration is scheduled to commence in the second quarter of 2025, with key deliverables including validated AI model, clinical decision-support tool, and regulatory pathway mapping for scaled commercial rollout. Ethics approvals and recruitment will commence as the next step.

Further updates during the course of the project will be provided as milestones are achieved.

HeraMED Limited
Managing Director & CEO
Anoushka Gungadin
M: +61 431 131 649
E: anoushka@hera-med.com

CFO & Company Secretary
Cameron Jones
T: +61 400 086 399
E: cameron.jones@bio101.com

Chairman
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

Media / Investor Relations
Matthew Wright
M: +61 451 896 420
E: matt@nwrcommunications.com.au

About Digital Health CRC

Digital Health CRC Limited connects government, academia and industry to accelerate the implementation and translation of evidence-based digital health technologies that solve the most pressing healthcare challenges. We are co-funded through the Commonwealth Government's Cooperative Research Centres (CRC) Program, and by our Participant organisations. https://digitalhealthcrc.com/

About RMIT

RMIT is a global university of technology, design and enterprise. One of Australia's original tertiary institutions, RMIT University enjoys an international reputation for excellence in professional and vocational education, applied research, and engagement with the needs of industry and the community.

https://www.rmit.edu.au/

About HeraMED Limited (ASX: HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.